Search tips
Search criteria

Results 1-25 (81)

Clipboard (0)

Select a Filter Below

Year of Publication
more »
2.  Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban 
Heart  2016;102(13):1036-1043.
To compare the characteristics and outcomes of patients with atrial fibrillation (AF) and aortic stenosis (AS) with patients with AF with mitral regurgitation (MR) or aortic regurgitation (AR) and patients without significant valve disease (no SVD).
Using Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) data, we analysed efficacy and safety outcomes, adjusting hazard ratios (HRs) for potential confounders using Cox regression analysis.
Among 14 119 intention-to-treat ROCKET AF trial patients, a trial that excluded patients with mitral stenosis or artificial valve prosthesis, 214 had AS with or without other valve abnormalities, 1726 had MR or AR and 12 179 had no SVD. After adjusting for prognostic factors, the composite of stroke, systemic embolism or vascular death increased approximately twofold in patients with AS (AS 10.84, MR or AR 4.54 and no SVD 4.31 events per 100 patient-years, p=0.0001). All-cause death also significantly increased (AS 11.22, MR or AR 4.90 and no SVD 4.39 events per 100 patient-years, p=0.0003). Major bleeding occurred more frequently in AS (adjusted HR 1.61, confidence intervals (CI) 1.03 to 2.49, p<0.05) and MR or AR (HR 1.30, 1.07 to 1.57, p<0.01) than in no SVD, but there was no difference between AS and MR or AR (HR 1.24, 0.78 to 1.97). The relative efficacy of rivaroxaban versus warfarin was consistent among patients with and without valvular disease. Rivaroxaban was associated with higher rates of major bleeding than warfarin in patients with MR or AR (HR 1.63, 1.15 to 2.31).
We found that patients with AF and AS on oral anticoagulants may have distinctly different efficacy and safety outcomes than patients with MR or AR or no SVD.
Trial registration number
NCT00403767; Post-results.
PMCID: PMC4941167  PMID: 26888572
3.  Editorial: CRISPR in Nucleic Acids Research 
Nucleic Acids Research  2016;44(17):8512.
PMCID: PMC5041476  PMID: 27382068
4.  Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF 
European Heart Journal  2016;37(38):2882-2889.
The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond the first year.
Methods and results
GARFIELD-AF is an ongoing, global observational study of adults with newly diagnosed NVAF. Two-year outcomes of 17 162 patients prospectively enrolled in GARFIELD-AF were analysed in light of baseline characteristics, risk profiles for stroke/systemic embolism (SE), and antithrombotic therapy. The mean (standard deviation) age was 69.8 (11.4) years, 43.8% were women, and the mean CHA2DS2-VASc score was 3.3 (1.6); 60.8% of patients were prescribed anticoagulant therapy with/without antiplatelet (AP) therapy, 27.4% AP monotherapy, and 11.8% no antithrombotic therapy. At 2-year follow-up, all-cause mortality, stroke/SE, and major bleeding had occurred at a rate (95% confidence interval) of 3.83 (3.62; 4.05), 1.25 (1.13; 1.38), and 0.70 (0.62; 0.81) per 100 person-years, respectively. Rates for all three major events were highest during the first 4 months. Congestive heart failure, acute coronary syndromes, sudden/unwitnessed death, malignancy, respiratory failure, and infection/sepsis accounted for 65% of all known causes of death and strokes for <10%. Anticoagulant treatment was associated with a 35% lower risk of death.
The most frequent of the three major outcome measures was death, whose most common causes are not known to be significantly influenced by anticoagulation. This suggests that a more comprehensive approach to the management of NVAF may be needed to improve outcome. This could include, in addition to anticoagulation, interventions targeting modifiable, cause-specific risk factors for death.
Clinical Trial Registration Unique identifier: NCT01090362.
PMCID: PMC5070447  PMID: 27357359
Atrial fibrillation; Anticoagulation; Stroke prevention; Stroke; Bleeding
5.  Editorial: CRISPR in Nucleic Acids Research 
Nucleic Acids Research  2016;44(11):4989-4990.
PMCID: PMC4914129  PMID: 27325109
6.  Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF 
Europace  2016;18(8):1135-1142.
The high costs associated with treatment for atrial fibrillation (AF) are primarily due to hospital care, but there are limited data to understand the reasons for and predictors of hospitalization in patients with AF.
Methods and results
The ROCKET AF trial compared rivaroxaban with warfarin for stroke prophylaxis in AF. We described the frequency of and reasons for hospitalization during study follow-up and utilized Cox proportional hazards models to assess for baseline characteristics associated with all-cause hospitalization. Of 14 171 patients, 14% were hospitalized at least once. Of 2614 total hospitalizations, 41% were cardiovascular including 4% for AF; of the remaining, 12% were for bleeding. Compared with patients not hospitalized, hospitalized patients were older (74 vs. 72 years), and more frequently had diabetes (46 vs. 39%), prior MI (23 vs. 16%), and paroxysmal AF (19 vs. 17%), but less frequently had prior transient ischaemic attack/stroke (49 vs. 56%). After multivariable adjustment, lung disease [hazard ratio (HR) 1.46, 95% confidence interval (CI) 1.29–1.66], diabetes [1.22, (1.11–1.34)], prior MI [1.27, (1.13–1.42)], and renal dysfunction [HR 1.07 per 5 unit GFR < 65 mL/min, (1.04–1.10)] were associated with increased hospitalization risk. Treatment assignment was not associated with differential rates of hospitalization.
Nearly 1 in 7 of the moderate-to-high-risk patients with AF enrolled in this trial was hospitalized within 2 years, and both AF and bleeding were rare causes of hospitalization. Further research is needed to determine whether care pathways directed at comorbid conditions among AF patients could reduce the need for and costs associated with hospitalization.
PMCID: PMC4974633  PMID: 27174904
Hospitalization; Atrial fibrillation; Outcomes; Stroke; Rivaroxaban
7.  Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF  
Pokorney, Sean D. | Piccini, Jonathan P. | Stevens, Susanna R. | Patel, Manesh R. | Pieper, Karen S. | Halperin, Jonathan L. | Breithardt, Günter | Singer, Daniel E. | Hankey, Graeme J. | Hacke, Werner | Becker, Richard C. | Berkowitz, Scott D. | Nessel, Christopher C. | Mahaffey, Kenneth W. | Fox, Keith A. A. | Califf, Robert M. | Anderson, J. | Bedwell, N. | Bilsker, M. | Bruce, G. | Agah, R. | DeSantis, M. | Eisenberg, S. | Flores, A. | Herzog, W. | Klein, S. | Snyder, H. | Krueger, S. | Almaguer, E. | Lavie, E. | Lee, C. | Mallis, G. | Modi, M. | Woodworth, G. | Niazi, I. | Peart, B. | Sundaram, S. | Snoddy, B. | Sotolongo, R. | Moloney, J. | Vijayaraghavan, K. | Whittier, F. | Yellen, L. | Banerjee, S. | Lustgarten, D. | Suresh, D. | Gelernt, M. | Levinson, L. | Ghanekar, R. | Kneller, G. | Hall, C. | Fadl, Y. | Pirwitz, M. | French, W. | Mayer, N. | Pugeda, J. | Steel, K. | Mody, F. | Malik, A. | Chandna, H. | Go, A. | Emlein, G. | Bowden, W. | Moscoso, R. | Hodson, R. | Berk, M. | Pan, D. | Pappas, J. | Orchard, R. | Lynchard, G. | Vijay, N. | Khan, W. | El Khadra, M | Antonishen, M. | Cucher, F. | Staab, M. | Zebrack, J. | Borromeo, S | Heilman, J. | Chaturvedi, S. | Makam, S. | Turk, S. | Hyers, T. | Williams, G. | Labroo, A. | Gill, S. | Myears, D. | Weinstein, J. | Shanes, J. | Chandrashekhar, Y. | Shah, S. | Reiter, W. | Logemann, T. | Almquist, A. | Bhagwat, R. | Tak, T. | Shen‐Ling, J. | Patel, P. | Artis, A. | Arouni, A. | Lauer, M. | Kinney, K. | Elsen, J. | Roan, P. | Villafria, R. | Sumpter, M. | Ip, J. | Welka, S. | Schifferdecker, B. | Sandoval, R. | Speirs, S. | Jones, A. | Haldis, T. | Kazmierski, J. | Sutherland, J. | Dietrich, D. | Telfer, E. | Berry, J. | McElveen, A. | Russell, J. | Sackett, M. | Antonios, N. | Smith, D. | Vora, K. | Kirby, A. | Lui, H. | Mego, D. | Ziada, K. | Navas, J. | Taussig, A. | Koren, M. | Vogel, C. | Saba, F. | Parrott, C. | Schneider, R. | Shirwany, A. | Rubin, M. | Treasure, C | Bertolet, B. | Chang, M. | Langberg, J. | Becker, R. | Cohen, Y. | McGrew, F. | White, J. | Arzola, F. | Zelenka, J. | Tannenbaum, A. | Fernandes, V. | Jamnadas, P. | Agamasu, J. | Collins, B. | Jauch, W. | Sasseen, B. | Hotchkiss, D. | Abadier, R. | Osunkoya, A. | Schlau, A. | Chappel, C. | Foster, M. | Braun, E. | Mostel, E. | Capo, J. | Ashchi, M. | Howard, V. | Albirini, A. | Burger, A. | Rolston, D. | Staniloae, C. | Bacon, J. | Wiseman, A. | McGarvey, J | Sonel, A. | Hamroff, G. | Chang, D. | Daboul, N. | Broderick, G. | Meholick, A. | Corbelli, J. | Silverman, R. | Raffetto, J. | Fishberg, R. | Georgeson, S. | Held, J. | Seidner, M. | Saint‐Jacques, H. | Heitner, J. | Kutalek, S. | Friedlander, I. | Hutchinson, B. | Walia, J. | Kondo, N. | Smiley, N. | Blitz, L. | Dale, H. | Sulman, S. | Szulawski, I. | Modares, F. | Martin, R. | Nahhas, A. | Renzi, M. | Akyea‐Djamson, A. | Alfieri, A. | Sandhu, J. | Voyce, S. | Amaram, S. | Meyerrose, G. | Shoukfeh, M. | Lee, F. | Villegas, B. | Idowu, O. | Khera, A. | Sam, C. | Vo, A. | Lieber, I. | Smith, T. | Awan, N. | Tsai, C. | Ganim, R. | Alzaghrini, G. | Pitt, W. | Shepherd, A. | Tang, S. | Stoltz, S. | Nelson, W. | Cox, S. | Meymandi, S. | Melucci, M. | Thomas, G. | Gogia, H. | Machell, C. | Chandrasekaran, S. | Brown, C. | Jetty, P. | Miller, G. | Dykstra, G. | Jaffrani, N. | Zakhary, B. | Caruso, A. | Zolty, R. | Fox, D. | Jacobs, G. | Lebenthal, M. | Mukherjee, S. | Zimetbaum, P. | Kingsley, J. | Jones, R. | Robinson, V. | Kenton, D. | Usedom, J. | Williams, S. | Snipes, C. | Wilson, V. | Hasty, R. | Shoemaker, J. | Donahue, M. | Al‐Saghir, Y. | Thomsen, E. | Yarows, S. | Chastain, S. | McLaughlin, P. | Wakham, M. | Shrestha, D. | Simmons, J. | Fisher, D. | Seymour, Z. | Frandsen, B. | First, B. | Sharpe, C. | Popeil, L. | Guthrie, R. | Hunter, J. | Alvarado, O. | Sandberg, J. | Gutman, N. | Belber, A. | Arkhipov, M. | Ballyzek, M. | Baranov, A. | Barbarash, O. | Barbarich, V. | Belenky, D. | Berkovich, O. | Bokarev, I. | Boyarkin, M. | Vaniev, S. | Volkova, E. | Gratsiansky, N. | Demin, A. | Zadionchenko, V. | Zateyshchikov, D. | Zrazhevsky, K. | Mazaev, V. | Martynov, A. | Mikhailov, S. | Mkrtchian, V. | Novozhenov, V. | Raskina, T. | Rebrov, A. | Sanina, N. | Simanekov, V. | Sitnikova, M. | Smolenskaya, O. | Stryuk, R. | Storozhakov, G. | Tankhilevich, B. | Tereschenko, S. | Khokhlov, A. | Khrustalev, O. | Chernov, S. | Shvarts, Y. | Shubik, Y. | Shulman, V. | Yakushin, S. | Bugrova, O. | Ivleva, A. | Libis, R. | Khozyainova, N. | Maslov, S. | Baranova, E. | Sherenkov, A. | Libov, I. | Lusov, V. | Chumakova, G. | Kuznetsov, V. | Ryamzina, I. | Reshetko, O. | Boldueva, S. | Alekseeva, N. | Novikova, T. | Dvornikov, V. | Idrisova, E. | Shostak, N. | Yarokhno, N. | Tebloev, K. | Treshkur, T. | Mazurov, V. | Loktin, E. | Sedavnyh, I. | Alexeeva, O. | Yakhontova, P. | Repin, A. | Izmozherova, N. | Kostenko, V. | Fokin, A. | Ketova, G. | Kouz, S. | Leader, R. | Ayala‐Paredes, F. | Luton, R. | Ma, P. | Pandey, S. | Pesant, Y. | Senior, R. | Vertes, G. | Bell, A. | Crowley, D. | Vizel, S. | Lasko, B. | Landry, D. | Berger, L. | Heath, J. | Bessoudo, R. | Ling, M. | Tellier, G. | Berlingieri, J. | Kafka, H. | Hill, L. | Mazza, G. | O'Mahony, W. | Chilvers, M. | O'Mahony, M. | Newman, D. | Silagy, S. | Heffernan, M. | Bennett, M. | Bhesania, T. | Rockman, G. | Ng, K. | Kalra, B. | Meneses, G. | Liang, W. | Cheung, M. | Kozak, J. | Pugen, G. | Vavougios, J. | Kates, M. | Nunes‐Vaz, C. | Jaffer, S. | Orfi, J. | Faiers, A. | Chung, C. | Felsen, S. | Bergman, S. | Bernstein, I. | Brownscombe, L. | Stockdill, J. | Silver, E. | Ezekiel, D. | Jagan, N. | Khurana, M. | Reisler, H. | Goldman, H. | Maung, T. | Wong, F. | Gillis, G. | Vexler, R. | Goldberg, B. | Luterman, M. | Gould, D. | Coutu, B. | Ouellet, A. | MacDonald, P. | Jones, M. | Collette, R. | Chong, P. | Fargher, T. | St‐Maurice, F. | Fortin, C. | Chehayeb, R. | Proulx, G. | Roy, R. | Liutkus, J. | Syan, G. | Rupka, D. | Lichtenstein, T. | Kooy, J. | Papastergiou, D. | Lubelsky, B. | Doyle, W. | Rajakumar, A. | Cha, J. | Choudhry, A. | Bhamjee, H. | Mawji, A. | Durfresne, M. | Constance, C. | Mutrie, J. | Najarali, A. | Warren, R. | Mucha, M. | Borts, D. | Nord, P. | Carrier, S. | Dawood, M. | Sabe‐Affaki, G. | Archibald, J. | Abram, N. | Teitelbaum, E. | Ebrahim, I. | Siebert, R. | van Zyl, L. | Theron, H. | Lloyd, E. | Sommers, R. | Podgorski, G. | Steingo, L. | Dalby, A. | Bayat, J. | Herbst, L. | Bester, F. | Corbett, C. | Bennett, J. | Roodt, A. | Roux, J. | Abelson, M. | Mohamed, Z. | Nortje, H. | Da Silva, A. | Nikolaides, K. | Liagkas, K. | Papasteriadis, E. | Achimastos, A. | Koliopoulos, N. | Trikas, A. | Manolis, A. | Ruiter, J. | Basart, D. | Crijns, H. | Withagen, A. | Janssen, M. | Van Langeveld, R | van Gelder, I. | Hamer, B. | Van Der Heijden, R | Hertzeberger, D. | Van Hessen, M | Pieterse, M. | Groutars, R. | Kuijper, A. | De Ruiter, G | van Boven, A. | Hoogslag, P. | Kragten, H. | Thijssen, H. | Veldkamp, R. | Scavee, C. | Heidbuchel, H. | Debruyne, P. | Deruyter, B. | El Ali, H | Goethals, M. | Cytryn, R. | Striekwold, H. | De Wolf, L | Goethals, P. | Provenier, F. | Hellemans, S. | Galinier, M. | Coisne, D. | Koenig, A. | Galley, D. | Destrac, S. | Leduc, J. | Rifai, A. | Citron, B. | Ellie, E. | Fournier, P. | Steg, G. | Landel, R. | Robinson, A. | Ziegler, F. | Boulliat, J. | Zuber, M. | Vida, M. | Galve Basilio, E. | Lopez, M. | Íñiguez, C. | Iglesias Alonso, L. | Cavero Gibanel, M. | Olivan Martinez, J. | Calvo Iglesias, F. | Marco Vera, P. | Bruguera Cortada, J. | Jaber Houbani, A. | Merino, J. | Olaz Preciado, F. | Balaguer, J. | de la Hera Galarza, J | Martinez Rubio, A. | Fontcuberta, J. | Sotillo Marti, J. | Gonzalez Juanatey, J. | Del Campo, R. | Vivanco, G. | Alvarez Garcia, P. | Pelayo, M. | Lippai, J. | Zamolyi, K. | Károly, T. | Vertes, A. | Nagy, A. | Kosa, I. | Janosi, A. | Lupkovics, G. | Kalo, E. | Forster, T. | Kis, E. | Tenczer, J. | Bereczki, D. | Komoly, S. | Csanyi, A. | Kiss, R. | Valikovics, A. | Dioszeghy, P. | Masini, F. | Terrosu, P. | Cirrincione, V. | Marabotti, C. | Cosmi, F. | Salvioni, A. | Binetti, G. | Piovaccari, G. | Nassiacos, D. | Boriani, G. | Calvi, V. | De Caterina, R | Pengo, V. | Parati, G. | Carolei, A. | D'Angelo, A. | Di Biase, M. | Fattore, L. | Agnelli, G. | Merlini, P. | Furlan, M. | Rasura, M. | Gandolfo, C. | Ageno, W. | Piovella, F. | Micieli, G. | Cinteza, M. | Fierbinteanu, C. | Natase‐Melicovici, D. | Ionescu, D. | Macarie, C. | Nanea, I. | Radoi, M. | Tatu‐Chitoiu, G. | Dragulescu, S. | Tudose, A. | Militaru, C. | Bengus, C. | Ungureanu, G. | Tau, A. | Popa, V. | Pirvu, O. | Bojinca, M. | Sipciu, D. | Popescu, M. | Chiru, M. | Vinereanu, D. | Tudoran, M. | Cojocaru, T. | Vintila, M. | Aron, G. | Petrascu, O. | Bolohan, F. | Baumgartner, R. | Sekoranja, L. | Vojacek, J. | Lacnak, B. | Kellnerova, I. | Dunaj, M. | Cihalik, C. | Janota, T. | Janousek, J. | Bouchal, P. | Spacek, R. | Choi Siruckova, J. | Heinc, P. | Vojtisek, P. | Pirchala, M. | Malecha, J. | Padour, F. | Linhart, A. | Mandysova, E. | Jandik, J. | Zidkova, E. | Sipula, D. | Ostadal, P. | Polasek, R. | Stransky, V. | Marcinek, G. | Rysava, D. | Osmancik, P. | Huber, K. | Drexel, H. | Brainin, M. | Eichinger‐Hasenauer, S. | Lang, W. | Pilger, E. | Moriarty, A. | Hudson, I. | Tang, K. | Cleland, J. | MacWalter, R. | Cooke, J. | McInnes, G. | Durairaj, R. | MacLeod, M. | Murdoch, D. | Kadr, H. | Lip, G. | Andrews, R. | Hunt, B. | Jackson, P. | Roffe, C. | Syed, H. | Bath, P. | Coyle, J. | Kelly, D. | Stender, S. | TorpPedersen, C. | Tuxen, C. | Jensen, G. | Melchior, T. | Klarlund, K. | Dahlstrom, C. | Nielsen, T. | Nielsen, E. | Bronnum‐Schou, J. | Sykulski, R. | Blomstrom, P. | Lindholm, C. | Wallen, T. | Nilsson, C. | Bertholds, E. | Carlsater, J. | Sirnes, P. | Elle, S. | Risberg, K. | Furuseth, K. | Skag, A. | Hoivik, H. | Landmark, N. | Kjaernli, T. | Berg‐Johansen, J. | Gradek, G. | Drzewiecki, A. | Pluta, W. | Szwed, H. | Trusz‐Gluza, M. | Ogorek, M. | Loboz‐Grudzien, K. | Ruszkowski, P. | Sciborski, R. | Kopaczewski, J. | Jaworska, K. | Kubica, J. | Opolski, G. | Hoffman, A. | Krzciuk, M. | Sinkiewicz, W. | Piotrowski, W. | Kolodziej, P. | Goszczynska, M. | Rynkiewicz, A. | Chojnowska, L. | Lewczuk, J. | Biedrzycka, M. | Piepiorka, M. | Kowal, J. | Karczmarczyk, A. | Pruszczyk, P. | Tendera, M. | Gaciong, Z. | Krzeminska‐Pakula, M. | Kornacewicz‐Jach, Z. | Kania, G. | Brachmann, J. | Lawall, H. | Guelker, H. | Spitzer, S. | MoebiusWinkler, S. | Dempfle, C. | Bode, C. | Darius, H. | Genth‐Zotz, S. | Sommer, S. | Roehnisch, J. | Strasser, R. | Daenschel, W. | Schwencke, C. | vom Dahl, J | Meuser, M. | Behrens‐Spandau, S. | Behrens‐Humbold, S. | Muegge, A. | Schoen, N. | Grooterhorst, P. | Ebert, H. | Kraemer, A. | Kohler, B. | Taggeselle, J. | Claus, G. | Sarnighausen, H. | Al‐Zoebi, A. | Schroeder, T. | Weissbrodt, M. | Lange, R. | Gabelmann, M. | Kaeaeb, S. | Doerr, M. | Boscher, D. | Bosch, R. | Sonntag, F. | Bauknecht, C. | Omran, H. | Leicht, M. | Veltkamp, R. | Hohensee, H. | Dieckmann, H. | Winkelmann, B. | Bernhardt, P. | Schnabel, A. | Kadel, C. | Proskynitopoulos, N. | Seidl, K. | Schellong, S. | Rios, C. | Guevara, C. | Coloma, R. | Torrejon, H. | Parra Galvan, J. | Drago Silva, J. | Gallegos, J. | Mendoza, A. | Negron, S. | Watanabe, L. | Medina, F. | Virgen Carrilo, L. | Alvarez Lopez, H. | Rodriguez, I. | Leiva‐Pons, J. | Baños Velasco, A. | Villarreal‐Careaga, J. | De los Rios, M | Gamba, M. | Llamas Esperon, G. | Villeda, E. | Ahuad Guerrero, A. | Alvariqueta, A. | Amuchastegui, M. | Bluguermann, J. | Caime, G. | Cuneo, C. | Gabito, A. | Garcia Brasca, D. | Hominal, M. | Jure, H. | Luquez, H. | Montana, O. | Piskorz, D. | Listorti, S. | Serra, J. | Sessa, H. | Varini, S. | Vita, N. | Aiub, J. | MacKinnon, I. | Chekherdemian, S. | Castagnino, J. | Cimbaro Canella, J. | Sgammini, H. | Escudero, A. | Albina, G. | Rapallo, C. | Balparda, C. | Chahin, M. | Fuentealba, V. | Riccitelli, M. | Casabe, J. | Lobo Marquez, L. | Kevorkian, R. | Cuadrado, J. | Dran, R. | Muntaner, J. | Gonzalez, M. | Cartasegna, L. | Hasbani, E. | Hrabar, A. | Sanchez, A. | Vogel, D. | Hershson, A. | Avezum, A. | Jaber, J. | Ernesto Leaes, P. | Bozza, A. | Lorga Filho, A. | Pimentel Filho, P. | Moura Jorge, J. | Maia, L. | Manenti, E. | D'Aurea Mora, R | de Souza Neto, J | Precoma, D. | Rabelo, A. | Rocha, J. | Rossi, P. | Kerr Saraiva, J. | Zimerman, L. | Bodanese, L. | Figueiredo, E. | de Souza, W. Sebba Barroso | Braga, J. | Alessi, S. | Gomes, M. | Silva, R. | Teixeira, M. | Costa, F. | Motta, M. | Sobral Filho, D. | Reis, G. | Garbelini, B | Zimmermann, S. | Pereira Barretto, A. | Dohmann, H. | Barreto Filho, J. | Ghorayeb, N. | Borelli, F. | Rossi dos Santos, F. | Lopes Prudente, M. | Vejar, M. | Lanas, F. | Del Pino, R. | Potthoff, S. | Charme, G. | Aguirre, A. | Saldana, A. | Garces, E. | Bunster, L. | Figueroa, H. | Olivares, C. | Raffo, C. | Vergara, E. | Sepulveda, P. | Jano, G. | Morales Alvarado, J. | Suarez, R. | Urina, M. | Perez, G. | Quintero, A. | Pava, L. | Botero Lopez, R. | Luengas, C. | Hernandez, E. | Sanchez, D. | Poveda, C. | Coronel, J. | Beltran, R. | Jaramillo, C. | Pardo, J. | Ponte Negretti, C. | Isea, J. | Vergara, G. | Morr, I. | Sim, K. | Wan Ahmad, W. | Yusof, Z. | Rosman, A. | Basri, H | Thompson, P. | Jeffery, I. | Purnell, P. | Roberts‐Thomson, P. | Heddle, W. | Waites, J. | Walters, D. | Amerena, J. | Challa, P. | Karrasch, J. | Lowy, A. | Fitzpatrick, D. | Parsons, M. | Phan, T. | Bladin, C. | Donnan, G. | Aroney, G. | Gerraty, R. | Anderson, C. | Blombery, P. | Martin, P. | Tissa Wijeratne, K. | Cross, D. | Crimmins, D. | Packham, D. | Jackson, D. | Chua, W. | Merino, R. | Magno, M. | Tirador, L. | Batalla, E. | Manalo, C. | Uy, N. | Ebo, G. | Reyes, E. | Bernan, A. | Richards, M. | Hart, H. | Mann, S. | Fisher, R. | Stewart, R. | Wilkins, G. | Barber, A. | Tan, R. | Ong, H. | Singh, R. | Sukonthasarn, A. | Tanomsup, S. | Krittayaphong, R. | Piamsomboon, C. | Piyayotai, D. | Sunsaneewitayakul, B. | Baek, S. | Seo, H. | Rim, S. | Kim, C. | Kim, K. | Ryu, K. | Jo, S. | Tahk, S. | Lee, H. | Kim, Y. | Shin, D. | Choi, Y. | Chung, N. | Namgung, J. | Hong, T. | Shin, W. | Jin, S. | Yan, X. | Fu, G. | Lu, G. | Yang, K. | Xu, D. | Chen, J. | Liu, J. | Wu, S. | Song, J.
Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors for all‐cause mortality may guide interventions.
Methods and Results
In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study, patients with nonvalvular atrial fibrillation were randomized to rivaroxaban or dose‐adjusted warfarin. Cox proportional hazards regression with backward elimination identified factors at randomization that were independently associated with all‐cause mortality in the 14 171 participants in the intention‐to‐treat population. The median age was 73 years, and the mean CHADS 2 score was 3.5. Over 1.9 years of median follow‐up, 1214 (8.6%) patients died. Kaplan–Meier mortality rates were 4.2% at 1 year and 8.9% at 2 years. The majority of classified deaths (1081) were cardiovascular (72%), whereas only 6% were nonhemorrhagic stroke or systemic embolism. No significant difference in all‐cause mortality was observed between the rivaroxaban and warfarin arms (P=0.15). Heart failure (hazard ratio 1.51, 95% CI 1.33–1.70, P<0.0001) and age ≥75 years (hazard ratio 1.69, 95% CI 1.51–1.90, P<0.0001) were associated with higher all‐cause mortality. Multiple additional characteristics were independently associated with higher mortality, with decreasing creatinine clearance, chronic obstructive pulmonary disease, male sex, peripheral vascular disease, and diabetes being among the most strongly associated (model C‐index 0.677).
In a large population of patients anticoagulated for nonvalvular atrial fibrillation, ≈7 in 10 deaths were cardiovascular, whereas <1 in 10 deaths were caused by nonhemorrhagic stroke or systemic embolism. Optimal prevention and treatment of heart failure, renal impairment, chronic obstructive pulmonary disease, and diabetes may improve survival.
Clinical Trial Registration
URL: Unique identifier: NCT00403767.
PMCID: PMC4943233  PMID: 26955859
atrial fibrillation; mortality; rivaroxaban; stroke; warfarin; Atrial Fibrillation; Sudden Cardiac Death; Heart Failure; Ischemic Stroke; Intracranial Hemorrhage
8.  Ambulatory heart rate range predicts mode-specific mortality and hospitalisation in chronic heart failure 
Heart  2015;102(3):223-229.
We aimed to define the prognostic value of the heart rate range during a 24 h period in patients with chronic heart failure (CHF).
Prospective observational cohort study of 791 patients with CHF associated with left ventricular systolic dysfunction. Mode-specific mortality and hospitalisation were linked with ambulatory heart rate range (AHRR; calculated as maximum minus minimum heart rate using 24 h Holter monitor data, including paced and non-sinus complexes) in univariate and multivariate analyses. Findings were then corroborated in a validation cohort of 408 patients with CHF with preserved or reduced left ventricular ejection fraction.
After a mean 4.1 years of follow-up, increasing AHRR was associated with reduced risk of all-cause, sudden, non-cardiovascular and progressive heart failure death in univariate analyses. After accounting for characteristics that differed between groups above and below median AHRR using multivariate analysis, AHRR remained strongly associated with all-cause mortality (HR 0.991/bpm increase in AHRR (95% CI 0.999 to 0.982); p=0.046). AHRR was not associated with the risk of any non-elective hospitalisation, but was associated with heart-failure-related hospitalisation. AHRR was modestly associated with the SD of normal-to-normal beats (R2=0.2; p<0.001) and with peak exercise-test heart rate (R2=0.33; p<0.001). Analysis of the validation cohort revealed AHRR to be associated with all-cause and mode-specific death as described in the derivation cohort.
AHRR is a novel and readily available prognosticator in patients with CHF, which may reflect autonomic tone and exercise capacity.
PMCID: PMC4752612  PMID: 26674986
9.  Systemic Atherosclerotic Inflammation Following Acute Myocardial Infarction: Myocardial Infarction Begets Myocardial Infarction 
Preclinical data suggest that an acute inflammatory response following myocardial infarction (MI) accelerates systemic atherosclerosis. Using combined positron emission and computed tomography, we investigated whether this phenomenon occurs in humans.
Methods and Results
Overall, 40 patients with MI and 40 with stable angina underwent thoracic 18F-fluorodeoxyglucose combined positron emission and computed tomography scan. Radiotracer uptake was measured in aortic atheroma and nonvascular tissue (paraspinal muscle). In 1003 patients enrolled in the Global Registry of Acute Coronary Events, we assessed whether infarct size predicted early (≤30 days) and late (>30 days) recurrent coronary events. Compared with patients with stable angina, patients with MI had higher aortic 18F-fluorodeoxyglucose uptake (tissue-to-background ratio 2.15±0.30 versus 1.84±0.18, P<0.0001) and plasma C-reactive protein concentrations (6.50 [2.00 to 12.75] versus 2.00 [0.50 to 4.00] mg/dL, P=0.0005) despite having similar aortic (P=0.12) and less coronary (P=0.006) atherosclerotic burden and similar paraspinal muscular 18F-fluorodeoxyglucose uptake (P=0.52). Patients with ST-segment elevation MI had larger infarcts (peak plasma troponin 32 300 [10 200 to >50 000] versus 3800 [1000 to 9200] ng/L, P<0.0001) and greater aortic 18F-fluorodeoxyglucose uptake (2.24±0.32 versus 2.02±0.21, P=0.03) than those with non–ST-segment elevation MI. Peak plasma troponin concentrations correlated with aortic 18F-fluorodeoxyglucose uptake (r=0.43, P=0.01) and, on multivariate analysis, independently predicted early (tertile 3 versus tertile 1: relative risk 4.40 [95% CI 1.90 to 10.19], P=0.001), but not late, recurrent MI.
The presence and extent of MI is associated with increased aortic atherosclerotic inflammation and early recurrent MI. This finding supports the hypothesis that acute MI exacerbates systemic atherosclerotic inflammation and remote plaque destabilization: MI begets MI.
Clinical Trial Registration
URL: Unique identifier: NCT01749254.
PMCID: PMC4599491  PMID: 26316523
18F-fluorodeoxyglucose positron emission and computed tomography; atherosclerosis; inflammation; vulnerable plaque
10.  Functionalizing Designer DNA Crystals with a Triple-Helical Veneer** 
DNA is a very useful molecule for the programmed self-assembly of 2D and 3D nanoscale objects.[1] The design of these structures exploits Watson–Crick hybridization and strand exchange to stitch linear duplexes into finite assemblies.[2–4] The dimensions of these complexes can be increased by over five orders of magnitude through self-assembly of cohesive single-stranded segments (sticky ends).[5,6] Methods that exploit the sequence addressability of DNA nanostructures will enable the programmable positioning of components in 2D and 3D space, offering applications such as the organization of nanoelectronics,[7] the direction of biological cascades,[8] and the structure determination of periodically positioned molecules by X-ray diffraction.[9] To this end we present a macroscopic 3D crystal based on the 3-fold rotationally symmetric tensegrity triangle[3,6] that can be functionalized by a triplex-forming oligonucleotide on each of its helical edges.
PMCID: PMC4037404  PMID: 24615910
DNA crystal; nanostructure; self-assembly; tensegrity; triple-helix
11.  Use and Outcomes of Antiarrhythmic Therapy in Patients with Atrial Fibrillation Receiving Oral Anticoagulation: Results from the ROCKET AF Trial 
Antiarrhythmic drugs (AAD) and anticoagulation are mainstays of atrial fibrillation (AF) treatment.
We aimed to study the use and outcomes of AAD therapy in anticoagulated AF patients.
Patients in the ROCKET AF trial (n=14,264) were grouped by AAD use at baseline: amiodarone, other AAD, or no AAD. Multivariable adjustment was performed to compare stroke, bleeding, and death across groups, as well as across treatment assignment (rivaroxaban or warfarin).
Of 14,264 patients randomized, 1681 (11.8%) were treated with an AAD (1144 [8%] with amiodarone, 537 [3.8%] with other AADs). Amiodarone-treated patients were less-often female (38% vs. 48%), had more persistent AF (64% vs. 40%), and more concomitant heart failure (71% vs. 41%) than patients receiving other AADs. Patients receiving no AAD more closely-resembled amiodarone-treated patients. Time in therapeutic range was significantly lower in warfarin-treated patients receiving amiodarone versus no AAD (50% vs. 58%, p<0.0001). Compared with no AAD, neither amiodarone (adjusted HR 0.98, 95% CI 0.74–1.31, p=0.9) nor other AADs (adjusted HR 0.66, 95% CI 0.37–1.17, p=0.15) were associated with increased mortality. Similar results were observed for embolic and bleeding outcomes. Rivaroxaban treatment effects in patients not on an AAD were consistent with the overall trial (primary endpoint adjusted HR 0.82, 95% CI 0.68–0.98, pinteraction=0.06; safety endpoint adjusted HR 1.12, 95% CI 0.90–1.24, pinteraction=0.33).
Treatment with AADs was not associated with increased morbidity or mortality in anticoagulated patients with AF. The influence of amiodarone on outcomes in patients receiving rivaroxaban requires further study.
PMCID: PMC4035424  PMID: 24833235
atrial fibrillation; antiarrhythmic drugs; rivaroxaban; warfarin; outcomes
12.  Sensitive Troponin Assay and the Classification of Myocardial Infarction 
The American Journal of Medicine  2015;128(5):493-501.e3.
Lowering the diagnostic threshold for troponin is controversial because it may disproportionately increase the diagnosis of myocardial infarction in patients without acute coronary syndrome. We assessed the impact of lowering the diagnostic threshold of troponin on the incidence, management, and outcome of patients with type 2 myocardial infarction or myocardial injury.
Consecutive patients with elevated plasma troponin I concentrations (≥50 ng/L; n = 2929) were classified with type 1 (50%) myocardial infarction, type 2 myocardial infarction or myocardial injury (48%), and type 3 to 5 myocardial infarction (2%) before and after lowering the diagnostic threshold from 200 to 50 ng/L with a sensitive assay. Event-free survival from death and recurrent myocardial infarction was recorded at 1 year.
Lowering the threshold increased the diagnosis of type 2 myocardial infarction or myocardial injury more than type 1 myocardial infarction (672 vs 257 additional patients, P < .001). Patients with myocardial injury or type 2 myocardial infarction were at higher risk of death compared with those with type 1 myocardial infarction (37% vs 16%; relative risk [RR], 2.31; 95% confidence interval [CI], 1.98-2.69) but had fewer recurrent myocardial infarctions (4% vs 12%; RR, 0.35; 95% CI, 0.26-0.49). In patients with troponin concentrations 50 to 199 ng/L, lowering the diagnostic threshold was associated with increased healthcare resource use (P < .05) that reduced recurrent myocardial infarction and death for patients with type 1 myocardial infarction (31% vs 20%; RR, 0.64; 95% CI, 0.41-0.99), but not type 2 myocardial infarction or myocardial injury (36% vs 33%; RR, 0.93; 95% CI, 0.75-1.15).
After implementation of a sensitive troponin assay, the incidence of type 2 myocardial infarction or myocardial injury disproportionately increased and is now as frequent as type 1 myocardial infarction. Outcomes of patients with type 2 myocardial infarction or myocardial injury are poor and do not seem to be modifiable after reclassification despite substantial increases in healthcare resource use.
PMCID: PMC4414368  PMID: 25436428
Myocardial infarction; Outcomes; Troponin; Type 2
13.  Functionalizing Designer DNA Crystals with a Triple-Helical Veneer** 
DNA is a very useful molecule for the programmed self-assembly of 2D and 3D nanoscale objects.[1] The design of these structures exploits Watson-Crick hybridization and strand exchange to stitch linear duplexes into finite assemblies.[2–4] The dimensions of these complexes can be increased by over five orders of magnitude through self-assembly of cohesive single-stranded segments (sticky-ends).[5,6] Methods that exploit the sequence addressability of DNA nanostructures will enable the programmable positioning of components in 2D and 3D space, offering applications such as the organization of nanoelectronics,[7] the direction of biological cascades,[8] and the structure determination of periodically positioned molecules by X-ray diffraction.[9] To this end we present a macroscopic 3D crystal based on the 3-fold rotationally symmetric tensegrity triangle[3,6] that can be functionalized by a triplex-forming oligonucleotide on each of its helical edges.
PMCID: PMC4037404  PMID: 24615910
DNA crystal; nanostructure; self-assembly; tensegrity; triple-helix
14.  Impact of Human Development Index on the profile and outcomes of patients with acute coronary syndrome 
Heart  2014;101(4):279-286.
To study the impact of national economic and human development status on patient profiles and outcomes in the setting of acute coronary syndrome (ACS).
We conducted a retrospective analysis of the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial (TRILOGY ACS) population (51 countries; 9301 patients). Outcome measures compared baseline characteristics and clinical outcomes through 30 months by 2010 country-level United Nations Human Development Indices (HDIs) and per-capita gross national income.
TRILOGY ACS enrolled 3659 patients from 27 very-high HDI countries, 3744 from 18 high-HDI countries and 1898 from 6 medium-HDI countries. Baseline characteristics of groups varied significantly, with the medium-HDI group having a lower mean age (63.0 years, vs 65.0 and 68.0 years for high-HDI and very-high HDI, respectively; p<0.001), lower baseline Global Registry of Acute Coronary Events risk score and lower rate of non-ST-segment elevation myocardial infarction (58.0%, vs 62.2% and 83.9% among high-HDI and very-high HDI, respectively). Medium-HDI and high-HDI patients had lower unadjusted 30-month rates for the composite of cardiovascular death/myocardial infarction/stroke (17.6%, 16.9% and 23.1% for medium-HDI, high-HDI and very-high HDI, respectively); this difference disappeared after adjusting for baseline characteristics. Adjusted HRs for the composite endpoint were lower in lower-income/middle-income countries vs upper-income/middle-income (0.791(95% CI 0.632 to 0.990)) and high-income countries (0.756 (95% CI 0.616 to 0.928)), with differences largely attributable to myocardial infarction rates.
Clinical patient profiles differed substantially by country HDI groupings. Lower unadjusted event rates in medium-HDI countries may be explained by younger age and lower comorbidity burden among these countries’ patients. This heterogeneity in patient recruitment across country HDI groupings may have important implications for future global ACS trial design.
Trial registration number
PMCID: PMC4345920  PMID: 25538134
15.  Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial 
In the ROCKET AF (Rivaroxaban–Once‐daily, oral, direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) trial, marked regional differences in control of warfarin anticoagulation, measured as the average individual patient time in the therapeutic range (iTTR) of the international normalized ratio (INR), were associated with longer inter‐INR test intervals. The standard Rosendaal approach can produce biased low estimates of TTR after an appropriate dose change if the follow‐up INR test interval is prolonged. We explored the effect of alternative calculations of TTR that more immediately account for dose changes on regional differences in mean iTTR in the ROCKET AF trial.
Methods and Results
We used an INR imputation method that accounts for dose change. We compared group mean iTTR values between our dose change–based method with the standard Rosendaal method and determined that the differences between approaches depended on the balance of dose changes that produced in‐range INRs (“corrections”) versus INRs that were out of range in the opposite direction (“overshoots”). In ROCKET AF, the overall mean iTTR of 55.2% (Rosendaal) increased up to 3.1% by using the dose change–based approach, depending on assumptions. However, large inter‐regional differences in anticoagulation control persisted.
TTR, the standard measure of control of warfarin anticoagulation, depends on imputing daily INR values for the vast majority of follow‐up days. Our TTR calculation method may better reflect the impact of warfarin dose changes than the Rosendaal approach. In the ROCKET AF trial, this dose change–based approach led to a modest increase in overall mean iTTR but did not materially affect the large inter‐regional differences previously reported.
Clinical Trial Registration
URL: Unique identifier: NCT00403767.
PMCID: PMC4392426  PMID: 25736441
anticoagulants; arrhythmia; embolism; prevention; risk factors
16.  Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States 
Vorapaxar is a protease‐activated receptor‐1 antagonist approved by the U.S. Food and Drug Administration (FDA) for the reduction of thrombotic cardiovascular (CV) events in patients with a history of myocardial infarction (MI) and peripheral artery disease (PAD), without a previous stroke or transient ischemic attack (TIA).
Methods and Results
We examined the efficacy and safety of vorapaxar in the intended use population, considering 20 170 patients randomized in the multinational, double‐blinded, placebo‐controlled TRA 2°P‐TIMI 50 trial. Of these, 16 897 qualified with a history of MI in the prior 2 weeks to 1 year and 3273 with PAD. At baseline 97% of the patients were treated with aspirin, 71% with a thienopyridine, and 93% a statin. At 3 years, the endpoint of CV death, MI, or stroke was significantly reduced with vorapaxar compared with placebo (7.9% versus 9.5%, HR, 0.80; 95% CI 0.73 to 0.89; P<0.001). Vorapaxar also significantly reduced the composite of CV death, MI, stroke, and urgent coronary revascularization (10.1% versus 11.8%, HR, 0.83; 95% CI 0.76 to 0.90; P<0.001), as well as the rate of CV death or MI (P<0.001). The safety endpoint of GUSTO moderate or severe bleeding, was increased in the vorapaxar group (3.7 versus 2.4, HR, 1.55; 95% CI 1.30 to 1.86, P<0.001). Intracranial bleeding (ICH) was 0.6% versus 0.4%, P=0.10 with vorapaxar versus placebo, with fatal bleeding 0.2% versus 0.2%; P=0.70.
In patients with prior MI or PAD who have not had a previous stroke or TIA, vorapaxar added to standard therapy is effective for long‐term secondary prevention of thrombotic CV events, while increasing moderate or severe bleeding.
Clinical Trial Registration
URL: Unique Identifier: NCT00526474.
PMCID: PMC4392433  PMID: 25792124
antiplatelet therapy; atherosclerosis; myocardial infarction; peripheral arterial disease; secondary prevention; vorapaxar
17.  Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial 
European Heart Journal  2013;35(4):233-241.
We investigated the prevalence of prior myocardial infarction (MI) and incidence of ischaemic cardiovascular (CV) events among atrial fibrillation (AF) patients.
Methods and results
In ROCKET AF, 14 264 patients with nonvalvular AF were randomized to rivaroxaban or warfarin. The key efficacy outcome for these analyses was CV death, MI, and unstable angina (UA). This pre-specified analysis was performed on patients while on treatment. Rates are per 100 patient-years. Overall, 2468 (17%) patients had prior MI at enrollment. Compared with patients without prior MI, these patients were more likely to be male (75 vs. 57%), on aspirin at baseline (47 vs. 34%), have prior congestive heart failure (78 vs. 59%), diabetes (47 vs. 39%), hypertension (94 vs. 90%), higher mean CHADS2 score (3.64 vs. 3.43), and fewer prior strokes or transient ischaemic attacks (46 vs. 54%). CV death, MI, or UA rates tended to be lower in patients assigned rivaroxaban compared with warfarin [2.70 vs. 3.15; hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.73–1.00; P = 0.0509]. CV death, MI, or UA rates were higher in those with prior MI compared with no prior MI (6.68 vs. 2.19; HR 3.04, 95% CI 2.59–3.56) with consistent results for CV death, MI, or UA for rivaroxaban compared with warfarin in prior MI compared with no prior MI (P interaction = 0.10).
Prior MI was common and associated with substantial risk for subsequent cardiac events. Patients with prior MI assigned rivaroxaban compared with warfarin had a non-significant 14% reduction of ischaemic cardiac events.
PMCID: PMC3896862  PMID: 24132190
Atrial fibrillation; Myocardial infarction; Coronary artery disease; Outcomes; Factor Xa; Rivaroxaban; Warfarin
18.  Thioester Bonds of Thiocoraline Can Be Replaced with NMe-Amide Bridges without Affecting Its DNA-Binding Properties 
In the search for new drug candidates for DNA recognition, affinity and sequence selectivity are two of the most important features. NMe-azathiocoraline, a synthetic antitumor bisintercalator derived from the natural marine product thiocoraline, shows similar potency to the parent compound, as well as possessing enhanced stability. Analysis of the DNA-binding selectivity of NMe-azathiocoraline by DNase I footprinting using universal substrates with all 136 tetranucleotides and all possible symmetrical hexanucleotide sequences revealed that, although this ligand binds to all CpG steps with lower affinities than thiocoraline, it displays additional binding to AT-rich sites. Moreover, fluorescence melting studies showed a strong interaction of the synthetic molecule with CACGTG and weaker binding to ACATGT and AGATCT. These findings demonstrate that NMe-azathiocoraline has the same mode of action as thiocoraline, mimicking its DNA-binding selectivity despite the substitution of its thioester bonds by NMe-amide bridges.
PMCID: PMC4027633  PMID: 24900772
Thiocoraline; bisintercalator; DNA binding; antitumor; DNase I footprinting; fluorescence melting
19.  High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study 
The BMJ  2015;350:g7873.
Objective To evaluate the diagnosis of myocardial infarction using a high sensitivity troponin I assay and sex specific diagnostic thresholds in men and women with suspected acute coronary syndrome.
Design Prospective cohort study.
Setting Regional cardiac centre, United Kingdom.
Participants Consecutive patients with suspected acute coronary syndrome (n=1126, 46% women). Two cardiologists independently adjudicated the diagnosis of myocardial infarction by using a high sensitivity troponin I assay with sex specific diagnostic thresholds (men 34 ng/L, women 16 ng/L) and compared with current practice where a contemporary assay (50 ng/L, single threshold) was used to guide care.
Main outcome measure Diagnosis of myocardial infarction.
Results The high sensitivity troponin I assay noticeably increased the diagnosis of myocardial infarction in women (from 11% to 22%; P<0.001) but had a minimal effect in men (from 19% to 21%, P=0.002). Women were less likely than men to be referred to a cardiologist or undergo coronary revascularisation (P<0.05 for both). At 12 months, women with undisclosed increases in troponin concentration (17-49 ng/L) and those with myocardial infarction (≥50 ng/L) had the highest rate of death or reinfarction compared with women without (≤16 ng/L) myocardial infarction (25%, 24%, and 4%, respectively; P<0.001).
Conclusions Although having little effect in men, a high sensitivity troponin assay with sex specific diagnostic thresholds may double the diagnosis of myocardial infarction in women and identify those at high risk of reinfarction and death. Whether use of sex specific diagnostic thresholds will improve outcomes and tackle inequalities in the treatment of women with suspected acute coronary syndrome requires urgent attention.
PMCID: PMC4301191  PMID: 25609052
20.  Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation 
Circulation  2014;129(18):1850-1859.
During long-term anticoagulation in atrial fibrillation, temporary interruptions (TIs) of therapy are common, but the relationship between patient outcomes and TIs has not been well studied. We sought to determine reasons for TI, the characteristics of patients undergoing TI, and the relationship between anticoagulant and outcomes among patients with TI.
Methods and Results
In the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF), a randomized, double-blind, double-dummy study of rivaroxaban and warfarin in nonvalvular atrial fibrillation, baseline characteristics, management, and outcomes, including stroke, non–central nervous system systemic embolism, death, myocardial infarction, and bleeding, were reported in participants who experienced TI (3–30 days) for any reason. The at-risk period for outcomes associated with TI was from TI start to 30 days after resumption of study drug. In 14 236 participants who received at least 1 dose of study drug, 4692 (33%) experienced TI. Participants with TI were similar to the overall ROCKET AF population in regard to baseline clinical characteristics. Only 6% (n=483) of TI incidences involved bridging therapy. Stroke/systemic embolism rates during the at-risk period were similar in rivaroxaban-treated and warfarin-treated participants (0.30% versus 0.41% per 30 days; hazard ratio [confidence interval]=0.74 [0.36–1.50]; P=0.40). Risk of major bleeding during the at-risk period was also similar in rivaroxaban-treated and warfarin-treated participants (0.99% versus 0.79% per 30 days; hazard ratio [confidence interval]=1.26 [0.80–2.00]; P=0.32).
TI of oral anticoagulation is common and is associated with substantial stroke risks and bleeding risks that were similar among patients treated with rivaroxaban or warfarin. Further investigation is needed to determine the optimal management strategy in patients with atrial fibrillation requiring TI of anticoagulation.
Clinical Trial Registration
URL: Unique identifier: NCT00403767.
PMCID: PMC4206548  PMID: 24552831
anticoagulation; atrial fibrillation; stroke
21.  Factors Associated With Major Bleeding Events 
This study sought to report additional safety results from the ROCKET AF (Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
The ROCKET AF trial demonstrated similar risks of stroke/systemic embolism and major/nonmajor clinically relevant bleeding (principal safety endpoint) with rivaroxaban and warfarin.
The risk of the principal safety and component bleeding endpoints with rivaroxaban versus warfarin were compared, and factors associated with major bleeding were examined in a multivariable model.
The principal safety endpoint was similar in the rivaroxaban and warfarin groups (14.9 vs. 14.5 events/100 patient-years; hazard ratio: 1.03; 95% confidence interval: 0.96 to 1.11). Major bleeding risk increased with age, but there were no differences between treatments in each age category (<65, 65 to 74, ≥75 years; pinteraction = 0.59). Compared with those without (n = 13,455), patients with a major bleed (n = 781) were more likely to be older, current/prior smokers, have prior gastrointestinal (GI) bleeding, mild anemia, and a lower calculated creatinine clearance and less likely to be female or have a prior stroke/transient ischemic attack. Increasing age, baseline diastolic blood pressure (DBP) ≥90 mm Hg, history of chronic obstructive pulmonary disease or GI bleeding, prior acetylsalicylic acid use, and anemia were independently associated with major bleeding risk; female sex and DBP <90 mm Hg were associated with a decreased risk.
Rivaroxaban and warfarin had similar risk for major/nonmajor clinically relevant bleeding. Age, sex, DBP, prior GI bleeding, prior acetylsalicylic acid use, and anemia were associated with the risk of major bleeding. (An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation: NCT00403767)
PMCID: PMC4206565  PMID: 24315894
anticoagulants; atrial fibrillation; hemorrhage
22.  Breakthrough Articles: Putting science first 
Nucleic Acids Research  2014;42(18):11273-11274.
PMCID: PMC4191420  PMID: 25301802
23.  Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial 
European Heart Journal  2014;36(5):288-296.
Anticoagulation prophylaxis for stroke is recommended for at-risk patients with either persistent or paroxysmal atrial fibrillation (AF). We compared outcomes in patients with persistent vs. paroxysmal AF receiving oral anticoagulation.
Methods and results
Patients randomized in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) trial (n = 14 264) were grouped by baseline AF category: paroxysmal or persistent. Multivariable adjustment was performed to compare thrombo-embolic events, bleeding, and death between groups, in high-risk subgroups, and across treatment assignment (rivaroxaban or warfarin). Of 14 062 patients, 11 548 (82%) had persistent AF and 2514 (18%) had paroxysmal AF. Patients with persistent AF were marginally older (73 vs. 72, P = 0.03), less likely female (39 vs. 45%, P < 0.0001), and more likely to have previously used vitamin K antagonists (64 vs. 56%, P < 0.0001) compared with patients with paroxysmal AF. In patients randomized to warfarin, time in therapeutic range was similar (58 vs. 57%, P = 0.94). Patients with persistent AF had higher adjusted rates of stroke or systemic embolism (2.18 vs. 1.73 events per 100-patient-years, P = 0.048) and all-cause mortality (4.78 vs. 3.52, P = 0.006). Rates of major bleeding were similar (3.55 vs. 3.31, P = 0.77). Rates of stroke or systemic embolism in both types of AF did not differ by treatment assignment (rivaroxaban vs. warfarin, Pinteraction = 0.6).
In patients with AF at moderate-to-high risk of stroke receiving anticoagulation, those with persistent AF have a higher risk of thrombo-embolic events and worse survival compared with paroxysmal AF.
PMCID: PMC4313363  PMID: 25209598
Atrial fibrillation; Paroxysmal; Persistent; Anticoagulation; Outcomes
24.  Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial 
European Heart Journal  2014;35(47):3377-3385.
We investigated clinical characteristics and outcomes of patients with significant valvular disease (SVD) in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) trial.
Methods and results
ROCKET AF excluded patients with mitral stenosis or artificial valve prostheses. We used Cox regression to adjust comparisons for potential confounders. Among 14 171 patients, 2003 (14.1%) had SVD; they were older and had more comorbidities than patients without SVD. The rate of stroke or systemic embolism with rivaroxaban vs. warfarin was consistent among patients with SVD [2.01 vs. 2.43%; hazard ratio (HR) 0.83, 95% confidence interval (CI) 0.55–1.27] and without SVD (1.96 vs. 2.22%; HR 0.89, 95% CI 0.75–1.07; interaction P = 0.76). However, rates of major and non-major clinically relevant bleeding with rivaroxaban vs. warfarin were higher in patients with SVD (19.8% rivaroxaban vs. 16.8% warfarin; HR 1.25, 95% CI 1.05–1.49) vs. those without (14.2% rivaroxaban vs. 14.1% warfarin; HR 1.01, 95% CI 0.94–1.10; interaction P = 0.034), even when controlling for risk factors and potential confounders. In intracranial haemorrhage, there was no interaction between patients with and without SVD where the overall rate was lower among those randomized to rivaroxaban.
Many patients with ‘non-valvular atrial fibrillation’ have significant valve lesions. Their risk of stroke is similar to that of patients without SVD after controlling for stroke risk factors. Efficacy of rivaroxaban vs. warfarin was similar in patients with and without SVD; however, the observed risk of bleeding was higher with rivaroxaban in patients with SVD but was the same among those without SVD. Atrial fibrillation patients with and without SVD experience the same stroke-preventive benefit of oral anticoagulants.
PMCID: PMC4265383  PMID: 25148838
Fibrillation; Anticoagulants; Heart diseases; Regurgitation; Stenosis
25.  The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study 
European Heart Journal  2014;36(6):377-384.
Acute coronary syndromes (ACSs) are driven by inflammation within coronary plaque. Interleukin-1 (IL-1) has an established role in atherogenesis and the vessel-response to injury. ACS patients have raised serum markers of inflammation. We hypothesized that if IL-1 is a driving influence of inflammation in non-ST elevation ACS (NSTE-ACS), IL-1 inhibition would reduce the inflammatory response at the time of ACS.
Methods and results
A phase II, double-blinded, randomized, placebo-controlled, study recruited 182 patients with NSTE-ACS, presenting <48 h from onset of chest pain. Treatment was 1:1 allocation to daily, subcutaneous IL-1receptor antagonist (IL-1ra) or placebo for 14 days. Baseline characteristics were well matched. Treatment compliance was 85% at 7 days. The primary endpoint (area-under-the-curve for C-reactive protein over the first 7 days) was: IL-1ra group, 21.98 mg day/L (95%CI 16.31–29.64); placebo group, 43.5 mg day/L (31.15–60.75) (geometric mean ratio = 0.51 mg/L; 95%CI 0.32–0.79; P = 0.0028). In the IL-1ra group, 14-day achieved high-sensitive C-reactive protein (P < 0.0001) and IL-6 levels (P = 0.02) were lower than Day 1. Sixteen days after discontinuation of treatment (Day 30) high-sensitive C-reactive protein levels had risen again in the IL-1ra group [IL-1ra; 3.50 mg/L (2.65–4.62): placebo; 2.21 mg/L (1.67–2.92), P = 0.022]. MACE at Day 30 and 3 months was similar but at 1 year there was a significant excess of events in the IL-1ra group.
IL-1 drives C-reactive protein elevation at the time of NSTE-ACS. Following 14 days IL-1ra treatment inflammatory markers were reduced. These results show the importance of IL-1 as a target in ACS, but also indicate the need for additional studies with anti-IL-1 therapy in ACS to assess duration and safety.
Clinical Trial Registration
EUCTR: 2006-001767-31-GB:
PMCID: PMC4320321  PMID: 25079365
Myocardial infarction; Drugs; Interleukins

Results 1-25 (81)